NCT04905277 (APO) is a Phase 2 clinical trial of Atenolol 50 MG in Healthy, sponsored by Sundeep Khosla, M.D..

Who is sponsoring NCT04905277?

NCT04905277 is sponsored by Sundeep Khosla, M.D..

What drugs are being tested in NCT04905277?

Interventions in NCT04905277: Atenolol 50 MG, Placebo.

Is NCT04905277 still recruiting?

NCT04905277 is currently active, enrolled. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT04905277: APO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atenolol for the Prevention of Osteoporosis (APO)

Active, enrolled Phase 2 Last updated 4 February 2026

What this trial tests

Phase 2 trial testing Atenolol 50 MG in Healthy in 420 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 July 2021

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	Sundeep Khosla, M.D.
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	420
Start date	27 July 2021
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	3 locations across United States

Drugs / interventions tested

Atenolol 50 MG — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Sundeep Khosla, M.D.

Who can join

Adults 50 to 75, female only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The crosstalk between bone remodeling and energy metabolism: A translational perspective.
Karsenty G, Khosla S. · · 2022 · cited 73× · PMID 35545088 · DOI 10.1016/j.cmet.2022.04.010
A neuronal action of sirtuin 1 suppresses bone mass in young and aging mice.
Luo N, Mosialou I, Capulli M, Bisikirska B, et al · · 2022 · cited 13× · PMID 36194488 · DOI 10.1172/jci152868
Propranolol Promotes Bone Formation and Limits Resorption Through Novel Mechanisms During Anabolic Parathyroid Hormone Treatment in Female C57BL/6J Mice.
Treyball A, Bergeron AC, Brooks DJ, Langlais AL, et al · · 2022 · cited 12× · PMID 35122666 · DOI 10.1002/jbmr.4523
Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?
Sfeir JG, Pignolo RJ. · · 2021 · cited 8× · PMID 34693190 · DOI 10.1002/jbm4.10538
Evidence in Humans for Bone as an Endocrine Organ Regulating Energy Metabolism.
Khosla S. · · 2023 · cited 6× · PMID 37576432 · DOI 10.1016/j.coemr.2023.100471
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone.
Lary CW, Atkinson EJ, Spillane J, Nayema Z, et al · · 2025 · cited 2× · PMID 39673185 · DOI 10.1093/jbmr/zjae200
Atenolol, alone or in combination with PTH, has a modest effect on bone in female C57BL/6J mice.
Fontaine RL, Brooks DJ, Barlow D, Neilson RJ, et al · · 2025 · PMID 40510866 · DOI 10.1093/jbmrpl/ziaf087
Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi-Omics and Multi-Modal Data Analysis.
Liu DY, Shen H, Greenbaum J, Yi QR, et al · · 2025 · PMID 40476595 · DOI 10.1002/cpt.3738

Verify or expand the search:

Other trials of Atenolol 50 MG

Trials testing the same drug.

NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Sundeep Khosla, M.D. trials

Trials by the same sponsor.

NCT04313634 — Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04905277 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sundeep Khosla, M.D.
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04905277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing